



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Neil H. Bander

Art Unit : 1774

Serial No. : 10/688,015

Examiner : Unknown

Filed : October 17, 2003

Title : METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING
INSULIN-RELATED DISORDERS USING BINDING AGENTS SPECIFIC FOR
PROSTATE SPECIFIC MEMBRANE ANTIGEN

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the attached form PTO-1449.

In accordance with 37 CFR 1.98 (a)(2)(i), only copies of foreign patent documents and non-patent references are enclosed.

This statement is being filed before the receipt of a first Office Action on the merits. No fee is believed to be due. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 20 July 2004

Rolando Medina
Rolando Medina, Ph.D., J.D.
Reg. No. 54,756

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20888691.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit

Signature

Typed or Printed Name of Person Signing Certificate

7/30/04
Nicole L. Babine
Nicole L. Babine



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10448-196001	Application No. 10/688,015
		Applicant Neil H. Bander	
		Filing Date October 17, 2003	Group Art Unit

**Information Disclosure Statement
by Applicant**
(Use several sheets if necessary)

(37 CFR §1.98(b))

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	4,454,106	Gansow et al.	June 12, 1984			
	AB	4,472,509	Gansow et al.	September 18, 1984			
	AC	4,814,275	Durda et al.	March 21, 1989			
	AD	4,855,353	Kurami et al.	August 8, 1989			
	AE	4,863,851	McEwan et al.	September 5, 1989			
	AF	4,863,854	Mattes et al.	September 5, 1989			
	AG	4,885,363	Tweedle et al.	December 5, 1989			
	AH	5,013,645	Kim	May 7, 1991			
	AI	5,053,503	Dean et al.	October 1, 1991			
	AJ	5,057,302	Johnson et al.	October 15, 1991			
	AK	5,118,611	Smith et al.	June 2, 1992			
	AL	5,130,118	Johnson et al.	July 14, 1992			
	AM	5,162,504	Horoszewicz	November 10, 1992			
	AN	5,198,208	Berg et al.	March 30, 1993			
	AO	5,208,324	Klaveness et al.	May 4, 1993			
	AP	5,217,704	Johnson et al.	June 8, 1993			
	AQ	5,227,471	Wright, Jr.	July 13, 1993			
	AR	5,229,289	Kjeldsen et al.	July 20, 1993			
	AS	5,314,996	Wright, Jr.	May 24, 1994			
	AT	5,342,924	Chang	August 30, 1994			
	AU	5,419,893	Berg et al.	May 30, 1995			
	AV	5,474,756	Tweedle et al.	December 12, 1995			
	AW	5,489,525	Pastan	February 6, 1996			
	AX	5,531,978	Berg et al.	July 2, 1996			
	AY	5,538,866	Israeli et al.	July 23, 1996			
	AZ	5,565,562	Parker et al.	October 15, 1996			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10448-196001	Application No. 10/688,015
		Applicant Neil H. Bander	
		Filing Date October 17, 2003	Group Art Unit

**Information Disclosure Statement
by Applicant**
(Use several sheets if necessary)

(37 CFR §1.98(b))

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AAA	5,578,484	Horoszewicz	November 26, 1996			
	ABB	5,599,677	Dowell et al.	February 4, 1997			
	ACC	5,639,879	Mease et al.	June 17, 1997			
	ADD	5,660,827	Thorpe et al.	August 26, 1997			
	AEE	5,674,470	Tweedle et al.	October 7, 1997			
	AFF	5,697,902	Goldenberg	December 16, 1997			
	AGG	5,763,202	Horoszewicz	June 9, 1998			
	AHH	5,776,427	Thorpe et al.	July 7, 1998			
	AII	5,804,602	Slusher et al.	September 8, 1998			
	AJJ	5,846,519	Tweedle et al.	December 8, 1998			
	AKK	5,855,866	Thorpe et al.	January 5, 1999			
	ALL	5,863,538	Thorpe et al.	January 26, 1999			
	AMM	5,877,289	Thorpe et al.	March 2, 1999			
	ANN	5,935,818	Israeli et al.	August 10, 1999			
	AOO	5,958,474	Lee et al.	September 28, 1999			
	APP	5,965,132	Thorpe et al.	October 12, 1999			
	AQQ	6,004,554	Thorpe et al.	December 21, 1999			
	ARR	6,004,555	Thorpe et al.	December 21, 1999			
	ASS	6,022,524	Maisano et al.	February 8, 2000			
	ATT	6,036,955	Thorpe et al.	March 14, 2000			
	AUU	6,051,230	Thorpe et al.	April 18, 2000			
	AVV	6,093,399	Thorpe et al.	July 25, 2000			
	AWW	6,143,274	Tweedle et al.	November 17, 2000			
	AXX	6,150,508	Murphy et al.	November 21, 2000			
	AYY	6,261,535	Thorpe et al.	July 17, 2001			
	AZZ	6,331,175	Goldenberg	December 18, 2001			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10448-196001	Application No. 10/688,015
		Applicant Neil H. Bander	
		Filing Date October 17, 2003	Group Art Unit

**Information Disclosure Statement
by Applicant**
(Use several sheets if necessary)

(37 CFR §1.98(b))

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AAAA	WO 86/06384	11/ 1986	PCT				
	ABBB	WO 88/02635	04/ 1988	PCT				
	ACCC	WO 89/00557	01/ 1989	PCT				
	ADDD	WO 89/06979	08/ 1989	PCT				
	AEEE	WO 91/15466	10/ 1991	PCT				
	AFFF	WO 93/17715	09/ 1993	PCT				
	AGGG	WO 93/19668	10/ 1993	PCT				
	AHHH	WO 94/04702	03/ 1994	PCT				
	AIII	WO 94/09820	05/ 1994	PCT				
	AJJJ	WO 94/26297	11/ 1994	PCT				
	AKKK	WO 95/26206	10/ 1995	PCT				
	ALLL	WO 95/31444	11/ 1995	PCT				
	AMMM	WO 96/26272	08/ 1996	PCT				
	ANNN	WO 96/39185	12/ 1996	PCT				
	AOOO	WO 96/40245	12/ 1996	PCT				
	APPP	WO 97/32862	09/ 1997	PCT				
	AQQQ	WO 97/35616	10/ 1997	PCT				
	ARRR	WO 99/43710	09/ 1999	PCT				
	ASSS	WO 00/50457	08/ 2000	PCT				
	ATTT	WO 00/52473	09/ 2000	PCT				
	AUUU	WO 00/74729	12/ 2000	PCT				
	AVVV	EP 0 208 531 B1	01/ 1987	Europe				
	AWWW	EP 0 232 751 B1	08/ 1987	Europe				
	AXXX	EP 0 233 619 B1	08/ 1987	Europe				
	AYYY	EP 0 279 397 B1	08/ 1988	Europe				
	AZZZ	EP 0 292 689 B1	11/ 1988	Europe				

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10448-196001	Application No. 10/688,015
	Applicant Neil H. Bander		
	Filing Date October 17, 2003	Group Art Unit	

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AAAAA	EP 0 299 795 A1	01/ 1989	Europe				
	ABBBB	EP 0 315 188 B1	05/ 1989	Europe				
	ACCCC	EP 0 382 583 B1	08/ 1990	Europe				
	ADDDD	EP 0 392 423 A2	10/ 1990	Europe				
	AEEEE	EP 0 466 200 A1	01/ 1992	Europe				
	AFFFF	EP 0 495 878 B1	07/ 1992	Europe				
	AGGGG	EP 0 594 739 B1	05/ 1994	Europe				
	AHHHH	EP 0 882 454 A2	12/ 1998	Europe				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AIIII	ATCC Deposit #HB9131 from June 24, 1986 (NOT AVAILABLE)
	AJJJJ	Barren et al. (1997), "Monoclonal Antibody 7E11.C5 Staining of Viable LNCaP Cells", Prostate 30(1):65-68.
	AKKKK	Carter et al. (1996), "Prostate-specific Membrane Antigen is a Hydrolase with Substrate and Pharmacologic Characteristics of a Neuropeptidase", Proc. Natl. Acad. Sci. U.S.A. 93:749-753.
	ALLLL	Chang et al. (1999), "Five Different Anti-Prostate-specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-associated Neovasculature", Cancer Research, 59(13):3192-3198.
	AMMMM	Diamond et al. (1997), "Monoclonal Antibody 225 Blockade of Prostate Specific Membrane Antigen (PSM) Expression: Potential Novel Therapy for Prostate Cancer", Journal of Urology 157(4 suppl):226 (Abstract 884).
	ANNNN	Dillman et al. (1988), "Toxicities Associated with Monoclonal Antibody Infusions in Cancer Patients", Mol. Biother. 1(2):81-85.
	AOOOO	Dillman et al. (1994), "Human Anti-Mouse Antibody Response in Cancer Patients Following Single Low-Dose Injections of Radiolabeled Murine Monoclonal Antibodies", Cancer Biotherapy 9(1):17-28.
	APPPP	Fair et al. (1997), "Prostate Specific Membrane Antigen", Prostate 32(2):140-148.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10448-196001	Application No. 10/688,015
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Neil H. Bander	
		Filing Date October 17, 2003	Group Art Unit
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AQQQQ	Harlow and Lane (1988), "Antibodies: A laboratory manual", Cold Spring Harbor Laboratory, p139-243.
	ARRRR	Heaton (1997), "Characterization and Glutamyl Preferring Carboxypeptidase Function of Prostate Specific Membrane Antigen: A Novel Folate Hydrolase", Urology 49(3A):104-112.
	ASSSS	Horszewicz et al. (1987), "Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients", Anticancer Research 7(5B):927-936.
	ATTTT	Israeli et al. (1993), "Molecular Cloning of a Complementary DNA Encoding a Prostate-Specific Membrane Antigen", Cancer Research 53(2):227-230.
	AUUUU	Israeli et al. (1994), "Expression of the Prostate-Specific Membrane Antigen", Cancer Research 54(7):1807-1811.
	AVVVV	Israeli et al. (1997), "Prostate Specific Membrane Antigen and Other Prostatic Tumor Markers on the Horizon", Urological Clinics of North America 24(2):439-450.
	AWWWW	Jain, R.K. (1990), "Vascular and interstitial barriers to delivery of therapeutic agents in tumors", Cancer and Metastasis Reviews 9(3):253-266.
	AXXXX	Leek et al. (1995), "Prostate-Specific Membrane Antigen: Evidence for the Existence of a Second Related Human Gene", British Journal of Cancer 72:583-588.
	AYYYY	Leung et al. (1986), "Selection of a Monoclonal Antibody to a New Prostate Cancer Marker for In Vivo Clinical Trials", 6 th International Congress of Immunology, p516 (Abstract 4.15.19).
	AZZZZ	Liu et al. (1997), "Monoclonal Antibodies to the Extracellular Domain of Prostate-specific Membrane Antigen also React with Tumor Vascular Endothelium", Cancer Research 57(18):3629-3634.
	AAAAA	Liu, et al. (1998), "Constitutive and Antibody-Induced Internalization of Prostate-Specific Membrane Antigen", Cancer Research 58(18):4055-4060.
	ABBBB	Murphy et al. (1995), "Comparison of Prostate Specific Antigen, Prostate Specific Membrane Antigen, and LNCaP-Based Enzyme-Linked Immunosorbent Assays in Prostatic Cancer Patients and Patients With Benign Prostatic Enlargement", The Prostate 26:164-168.
	ACCCC	Murphy et al. (1995), "Comparison of Prostate Specific Membrane Antigen, and Prostate Specific Antigen Levels in Prostatic Cancer Patients", Anticancer Res. 15:1473-1480.
	ADDDD	Murphy et al. (1996), "Measurement of Prostate-Specific Membrane Antigen in the Serum With a New Antibody", The Prostate 28(4):266-271.
	AEEEE	Pinto et al. (1996), "Prostate-Specific Membrane Antigen: A Novel Folate Hydrolase in Human Prostatic Carcinoma Cells", Clinical Cancer Research 2(9):1445-1451.
	AFFFF	Rochon et al. (1994), "Western Blot Assay for Prostate-Specific Membrane Antigen in Serum of Prostate Cancer Patients", The Prostate 25(4):219-223.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10448-196001	Application No. 10/688,015
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Neil H. Bander	
		Filing Date October 17, 2003	Group Art Unit
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AGGGGC	Schlom (1991), "Monoclonal antibodies: They're more and less than you think", Molecular Foundations of Oncology, ed. Broder, Williams & Wilkins, p95-134.
	AHHHHH	Silver et al. (1997), "Prostate-specific Membrane Antigen Expression in Normal and Malignant Human Tissues", Clinical Cancer Research 3:81-85.
	AIIII	Su et al. (1995), "Alternatively Spliced Variants of Prostate-specific Membrane Antigen RNA: Ratio of Expression as a Potential Measurement of Progression", Cancer Research 55:1441-1443.
	AJJJJ	Troyer et al. (1994), "Subcellular Localization of the 7E11-C5 Prostate Specific Antigen", Proc. Am. Assoc. Cancer Research 35:283 (Abstract 1688).
	AKKKKK	Troyer et al. (1995), "Biochemical Characterization and Mapping of the 7E11-C5.3 Epitope of the Prostate-Specific Membrane Antigen", Urol Oncol 1:29-37.
	ALLLLL	Troyer et al. (1995), "Detection and Characterization of the Prostate-Specific Membrane Antigen (PSMA) in Tissue Extracts and Body Fluids", International Journal of Cancer 62(5):552-558.
	AMMMMM	Troyer et al. (1997), "Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line", Prostate 30(4):232-242.
	ANNNNN	Uria et al. (1997), "Prostate Specific Membrane Antigen in Breast Carcinoma", The Lancet 349(9065):1601.
	AOOOOC	Wang et al. (1988), "Monoclonal Antibody Assays for Prostatic Tumor", Immunol Ser 39:195-219.
	APPPPP	Wright (1990), "Characterization of a New Prostate Carcinoma-Associated Marker: 7E11-C5", Antibody Immunoconjugates and RadioPharmaceuticals 3:Abstract 193.
	AQQQQQ	Wright et al. (1995), "Expression of Prostate-Specific Membrane Antigen in Normal, Benign, and Malignant Prostate Tissues", Urol Oncol, 1:18-28.
	ARRRRR	Yang et al. (1998), "Alpha particle emitter therapy of micrometastases: ²¹³ Bi-J5 (anti-PSMA) treatment of LNCaP spheroids", Proceedings of the American Association for Cancer Research 39:440 (Abstract #2996).

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	